Page last updated: 2024-12-08
soyasapogenol a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
soyasapogenol A: RN refers to (3beta,4beta,21beta,22beta)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
soyasapogenol A : A pentacyclic triterpenoid that is oleanane containing a double bond between positions 12 and 13 and substituted by hydroxy groups at the 3beta, 21beta, 22beta and 24-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 12442849 |
| CHEMBL ID | 1762006 |
| CHEBI ID | 62440 |
| SCHEMBL ID | 828826 |
| MeSH ID | M0299706 |
Synonyms (21)
| Synonym |
|---|
| soyasapogenol a |
| C17419 |
| 508-01-0 |
| CHEBI:62440 , |
| CHEMBL1762006 |
| (3beta,4beta,21beta,22beta)-olean-12-ene-3,21,22,23-tetrol |
| 3beta,21beta,22beta,24-tetrahydroxyolean-12-ene |
| soyasapogenol-a |
| (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol |
| unii-43t6j3o9wl |
| olean-12-ene-3,21,22,23-tetrol, (3beta,4beta,21beta,22beta)- |
| 43t6j3o9wl , |
| olean-12-ene-3.beta.,21.beta.,22.beta.,24-tetrol |
| olean-12-ene-3,21,22,23-tetrol, (3.beta.,4.beta.,21.beta.,22.beta.)- |
| SCHEMBL828826 |
| soyasapogenol a(p) |
| AKOS032945989 |
| Q27131898 |
| CS-0032501 |
| HY-N6073 |
| MS-28813 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The bioavailability and absorption of soyasaponins and soyasapogenols remain unclear; therefore, the aim of this study was to evaluate plasma soyasaponin and soyasapogenol concentrations and absorption characteristics." | ( Comparison of bioavailability (I) between soyasaponins and soyasapogenols, and (II) between group A and B soyasaponins. Kamo, S; Sato, T; Suzuki, S, 2014) | 0.4 |
| "These results suggest that bioavailability of soyasapogenols is better than that of corresponding soyasaponins and that of group B soyasaponins is better than that of group A soyasaponins." | ( Comparison of bioavailability (I) between soyasaponins and soyasapogenols, and (II) between group A and B soyasaponins. Kamo, S; Sato, T; Suzuki, S, 2014) | 0.4 |
| "Research suggests that soyasaponins are poorly absorbed in the GI tract and that soyasaponin aglycones or soyasapogenols are absorbed faster and in greater amounts than the corresponding soyasaponins." | ( The Fate and Intermediary Metabolism of Soyasapogenol in the Rat. Pan, C; Yan, Y; Zhao, D, 2022) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| pentacyclic triterpenoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID589618 | Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 50 ug/ml after 24 hrs | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589616 | Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 200 ug/ml after 24 hrs | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589628 | Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells at 25 to 200 ug/ml measured after 24 hrs by Griess reaction method | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589619 | Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 25 ug/ml after 24 hrs | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589622 | Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 100 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589617 | Inhibition of iNOS activity in LPS-stimulated mouse RAW264.7 cells assessed as conversion of L-[14H] arginine to L-[3H] citruline per mg of protein at 100 ug/ml after 24 hrs | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589530 | Cytotoxicity against mouse RAW264.7 cells at 25 to 200 ug/ml after 24 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589624 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha release by ELISA | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID1831041 | Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay | 2021 | Bioorganic & medicinal chemistry, 12-15, Volume: 52 | Microbial transformation of pentacyclic triterpenes for anti-inflammatory agents on the HMGB1 stimulated RAW 264.7 cells by Streptomyces olivaceus CICC 23628. |
| AID589621 | Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 50 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589625 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release by ELISA | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589623 | Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 200 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID589620 | Inhibition of iNOS mRNA expression in LPS-stimulated mouse RAW264.7 cells at 25 ug/ml after 24 hrs by real time fluorescent quantitative real time PCR relative to negative control | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| AID86198 | Hepatoprotective activity against aflatoxin B1 (10e-5 M) induced Hep G2 cells at a dose of 10 ug/ml | 1998 | Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6 | Derivatization of soyasapogenol A and their hepatoprotective activities. |
| AID589626 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1 release by ELISA | 2011 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8 | Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||